05:47 PM EDT, 10/15/2024 (MT Newswires) -- Marinus Pharmaceuticals ( MRNS ) said late Tuesday it secured a new patent from the US Patent and Trademark Office for Ztalmy, or ganaxolone, oral titration regimens covering the treatment of various epilepsy disorders.

The patent is scheduled to expire in September 2042, the company said.

Marinus shares were up 5.2% in after-hours activity.

Price: 1.8300, Change: +0.09, Percent Change: +5.17